A method for culturing primary cells of gastric cancer and gallbladder cancer and cholangiocarcinoma and auxiliary reagents. A method for culturing primary cells of gastric cancer and gallbladder cancer and cholangiocarcinoma and auxiliary reagents. The core of the technology is that: (1) the solid tumor tissues of gastric cancer and gallbladder cancer and cholangiocarcinoma are treated with a mild cell dissociation reagent, and the primary tumor cells of gallbladder cancer and cholangiocarcinoma in a bile sample are isolated by a mild method to ensure the vitality of cancer cells to the greatest extent; (2) a special serum-free medium is prepared, and tumor cells of gastric cancer and gallbladder cancer and cholangiocarcinoma are cultured in vitro by a suspension culture system to eliminate the interference of normal cells to the greatest extent while ensuring normal amplification of cancer cells.

The present disclosure provides a method of separating hematopoietic stem cells from umbilical cord blood, including the following steps: a hydroxyethyl starch solution is added into cord blood and mixed uniformly, then centrifuged to get an upper liquid layer and a lower erythrocyte layer; the liquid in the upper layer and the erythrocytes in the lower layer are centrifuged respectively; an upper plasma layer and a basal cell layer are obtained after the centrifugation of the upper liquid layer, the cells in the basal layer are resuspended; a superficial buffy-coat layer is obtained after the centrifugation of the erythrocytes, and the superficial buffy-coat layer is metered with the plasma in the upper layer, and then centrifuged to get a lower cell layer, which is precipitated to remove erythrocytes and then resuspended; the above resuspended cells are added into freezing medium, mixed uniformly and then stored in a liquid nitrogen tank.

Described herein are hybrid nanoparticles that are exosomes loaded with one or more nanoparticle dendrimers. Also included are pharmaceutical compositions including the hybrid nanoparticles and methods of making the hybrid nanoparticles. Also described is a method of treating a human subject by administering to the human subject the above-described hybrid nanoparticles.

This application relates to a method of making a cell construct, comprising a) plating a plurality of cells on a substantially flat surface; b) growing the plurality of cells to at least 80% confluent to form a cell sheet with intercellular linkages; c) applying a culture medium having a pH of about 5 to about 6.8 to the cell sheet; d) replacing the culture medium of step c) with a culture medium having a pH of about 7.5 to about 8.5; and e) replacing the culture medium of step d) with a culture medium having a pH of about 7 to about 7.7, to obtain a substantially planar untethered cell sheet. Also provided is a cell construct formed according to the method and uses thereof.

The present disclosure provides methods for generating retinal cell clusters for use in cellular component transfer therapy, retinal cell clusters generated by such methods, and compositions comprising such retinal cell clusters. The present disclosure also provides uses of the retinal cell clusters and compositions comprising thereof for preventing and/or treating inherited retinal degenerative diseases.

The present invention relates to the field of biotechnology and aims to provide a YAP1 gene-modified mesenchymal stem cell and a method for preparing the same. The mesenchymal stem cell is a primary mesenchymal stem cell modified by overexpressed YAP1 gene, wherein the YAP1 gene is derived from a YAP1 lentiviral vector or a YAP1 plasmid vector, and the primary mesenchymal stem cell is derived from any of the following human tissues: placenta, umbilical cord or adipose tissue. The YAP1 gene-modified mesenchymal stem cell obtained by the present invention has no effect on the phenotype and differentiation ability of MSCs themselves; the present invention can significantly promote the proliferation of mesenchymal stem cell and further increase the cell yield by modifying the mesenchymal stem cell with overexpressed YAP1 gene; therefore, a large number of mesenchymal stem cells can be rapidly obtained for clinical stem cell transplantation therapy.

Methods of culturing and manufacturing of cells on a large-scale level are disclosed. Particularly, a manufacturing system and device, and methods of using the system and device for culturing and manufacturing cells in hollow fibers made from alginate polymers are provided.

The invention relates to placenta-derived matrix, methods of preparing, and methods of use thereof. The invention also relates to methods of culturing cells, delivering cells, promoting differentiation of stem cells or tissue-specific progenitor cells, and repairing, replacing, regenerating, filling, reducing or inhibiting scarring of defects using the same. The invention further relates to methods of coating placenta-derived matrix on a surface or injecting the placenta-derived matrix into a site of interest.

Degradable hollow shell particles are disclosed that can encapsulate cells within the hollow inner cavity that allows for the high-throughput screening and sorting of the encapsulated cells based on their phenotypic properties. The solid-phase of the particle is porous such that solution exchange can occur between the external environment and the interior cavity. Further, the solid-phase contains degradable crosslinkers and can be degraded to release enclosed biological entities. An example embodiment consists of encapsulating a cell within the hollow shell particle, allowing the cell to accumulate biomass, selecting hollow shell particles based on accumulated biomass, and degrading the hollow shell particles to release the cells and develop hyper-producing cell lines. Exemplary cell types include microalgae, mammalian cells, bacteria, yeast, and fungi.

A cell clump dispersing device for dispersing cell clumps is provided, including a dispersion structure module that includes at least one structure for providing fluid flow shear force. Each structure for providing liquid flow shear force includes an inlet for cell clumps to be dispersed to enter the structure, and at least one outlet for dispersed cell clumps to flow out of the structure. A diameter of the outlet is smaller than that of the inlet, and an end of at least one of the structure is capable of being connected to an end of another of the structure.